Oxford Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Oxford Asset Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,982	Closed	-$237K	–	1523
2019 Q4	$237K	Buy	+2,982	New	+$177K	0.01%	1503
2018 Q4	–	Sell	-46,966	Closed	-$1.79M	–	2204
2018 Q3	$1.79M	Buy	46,966 +26,996	+135%	+$1.2M	0.04%	726
2018 Q2	$923K	Buy	19,970 +5,629	+39%	+$256K	0.02%	1080
2018 Q1	$693K	Sell	14,341 -13,783	-49%	-$769K	0.01%	1107
2017 Q4	$1.11M	Sell	28,124 -1,565	-5%	-$58.5K	0.02%	886
2017 Q3	$900K	Sell	29,689 -38,397	-56%	-$1.08M	0.02%	982
2017 Q2	$1.86M	Sell	68,086 -50,409	-43%	-$1.5M	0.04%	640
2017 Q1	$4.37M	Sell	118,495 -22,350	-16%	-$563K	0.11%	182
2016 Q4	$2.04M	Buy	140,845 +102,200	+264%	+$1.8M	0.07%	323
2016 Q3	$891K	Buy	+38,645	New	+$737K	0.03%	539

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Oxford Asset Management's GBT Position: Q1 2020 in Review

Oxford Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2020, closing a stake of 2,982 shares — an estimated $237K sold.

Oxford Asset Management first reported a position in GBT in Q3 2016 and held it in 10 quarters. The position peaked at $4.37M in Q1 2017. 220 funds tracked by Wall St. Rank hold GBT as of Q1 2020.

Oxford Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 2,982 Global Blood Therapeutics, Inc. shares in Q1 2020, an estimated $237K.
Oxford Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2016 and held it in 10 quarters.
Oxford Asset Management's Global Blood Therapeutics, Inc. position peaked at $4.37M in Q1 2017.
220 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.